Pioneering targeted epigenetic modulation through selective Histone Deacetylase 6 (HDAC6) inhibitors is establishing a vital therapeutic frontier across neurodegenerative disorders, peripheral neuropathies, and oncology. Detailed analysis within the Histone Deacetylase 6 Market report demonstrates how isoform-selective HDAC6 inhibitor small molecules disrupt cytoplasmic tubulin deacetylation...